Drugs / 161Tb-LNC1011
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07381582 | Jan 2026 → Oct 2027 expected | prostate cancer | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 161Tb-LNC1011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07381582 ↗ |
| Route | Intravenous | “Patients will receive intravenous 161Tb-LNC1011 starting at 50 mCi with planned dose-level escalations to 80, 130 and 200 mCi (±10%).” NCT07381582 ↗ |